文献速递食管与纵隔外科

新辅助免疫化疗对比新辅助放化疗治疗局部晚期食管鳞癌

Neoadjuvant Immuno-Chemotherapy Versus Neoadjuvant Chemoradiotherapy in Locally Advanced Oesophageal Squamous Cell Carcinoma.
PubMed 文献 · Eur J Cardiothorac Surg · 2025-01-01

该回顾性研究比较NICE(卡瑞利珠单抗联合卡铂+紫杉醇)与CROSS(卡铂+紫杉醇同步41.4 Gy放疗)方案治疗局部晚期食管鳞癌的疗效。

要点

  • NICE组3年总生存和肿瘤特异性生存均优于CROSS组
  • 非pCR患者中NICE组总生存优于CROSS组(HR 1.86,95%CI 1.24-2.77)

核心结论

  • NICE方案较CROSS方案带来更优的长期生存,且复发模式相似。
  • 辅助免疫治疗可能是NICE后残留病理疾病患者长期获益的重要因素。

研究设计与样本

  • 回顾性分析2018年1月至2022年4月接受NICE或CROSS方案的患者。
  • NICE方案为卡瑞利珠单抗联合卡铂和紫杉醇,共两个21天周期。
  • CROSS方案为卡铂和紫杉醇化疗同步41.4 Gy放疗。
  • 倾向性匹配后每组177例患者纳入分析。

主要发现

  • 局部和远处复发率两组相当。
  • 亚组分析:pCR患者生存无差异(HR 1.65,95%CI 0.56-4.84);非pCR患者NICE组总生存更优(HR 1.86,95%CI 1.24-2.77)。

临床怎么用

  • 对于局部晚期食管鳞癌,NICE方案可作为CROSS之外的潜在新辅助治疗选择。
  • NICE治疗后非pCR患者可能从辅助免疫治疗中获益。

局限性

  • 回顾性研究设计可能存在选择偏倚。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The chemoradiotherapy for oesophageal cancer followed by surgery study (CROSS) regimen has been the standard neoadjuvant treatment for oesophageal squamous cell carcinoma over the last decade. However, the emerging Neoadjuvant Immuno-Chemotherapy followed by Esophagectomy (NICE) regimen has shown promising potential. This study compares the treatment response and the long-term outcomes of NICE versus CROSS for oesophageal squamous cell carcinoma. METHODS: We retrospectively analysed patients who underwent the NICE or the CROSS regimen between January 2018 and April 2022. NICE comprised camrelizumab with carboplatin and paclitaxel over two 21-day cycles. CROSS included carboplatin and paclitaxel chemotherapy with concurrent radiotherapy (41.4 Gy) per protocol. After matching, 177 patients were included in each group for analysis. RESULTS: The pathological complete remission (pCR) rates were similar between the NICE and the CROSS (20.9% vs 25.4%, P = .314) regimens. NICE demonstrated superior 3-year overall survival (73.5% vs 58.4%, P = .003) and cancer-specific survival (77.3% vs 64.3%, P = .006). Recurrence rates, including local and distant recurrences, were comparable. Subgroup analysis revealed no survival differences in patients with a pCR (hazard ratio 1.65, 95% CI 0.56-4.84), but patients without non-pCR in the NICE group showed improved overall survival compared to those in the CROSS (hazard ratio 1.86, 95% CI 1.24-2.77) group. Patients following NICE reported higher proportions of adjuvant therapy than those following CROSS (P < .001) and were largely driven by immunotherapy (OR 5.45). Furthermore, in multivariable analysis, receipt of adjuvant therapy was identified as a significant promoter for improving long-term prognosis after NICE. CONCLUSIONS: NICE offers better survival than CROSS with similar recurrence patterns. Adjuvant immunotherapy might be an important factor for long-term benefits in residual pathological disease after NICE.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Yang Y, Yuan C, Li B, et al. Neoadjuvant Immuno-Chemotherapy Versus Neoadjuvant Chemoradiotherapy in Locally Advanced Oesophageal Squamous Cell Carcinoma. Eur J Cardiothorac Surg. 2025. PMID: 40973658. doi:10.1093/ejcts/ezaf302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。